FDA approval of Pfizer nasal spray migraine drug Zavzpret final week means a $475 million payday for Royalty Pharma. The cost stems from a financing deal Pfizer inherited when it acquired rights to the drug final 12 months.
Zavzpret, which was identified in growth as zavegepant, was initially developed by Biohaven Prescription drugs. Below a 2018 deal, Royalty Pharma paid Biohaven $100 million up entrance in alternate for the correct to obtain funds tied to income from gross sales of two migraine medication, one intranasal and the opposite one an oral drug.
The oral drug, Nurtec ODT, was permitted in 2020. Later that 12 months, Biohaven and Royalty Pharma expanded their settlement so as to add success-based milestone funds, the primary of which is a cost upon the FDA approval of the intranasal drug now generally known as Zavzpret. That’s the $475 million cost that Royalty Pharma introduced on Thursday.
Each Nurtec and Zavzpret are a part of a brand new class of migraine medication that block calcitonin gene-related peptide, a protein related to the onset of migraine ache. The primary CGRP inhibitors had been giant molecule medication administered as infusions or injections. Nurtec, a small molecule, is dosed as a quick-dissolving pill positioned below the tongue. The drug’s preliminary approval was for the therapy of acute migraine ache. In 2021, the Nurtec received an further FDA approval for migraine prevention.
Nurtec offers migraine ache reduction inside an hour. Intranasal Zavzpret is designed to work much more rapidly, taking impact as quickly as quarter-hour. The drug’s approval final Friday makes it the one permitted intranasal CGRP inhibitor. Pfizer mentioned it expects to the product might be out there in pharmacies in July.
Clinicians say intranasal dosing provides migraine sufferers extra choices in choosing essentially the most acceptable therapy. Shae Datta, a neurologist and migraine knowledgeable from NYU Langone Well being, mentioned in an emailed assertion that sufferers with difficult-to-treat migraines usually have nausea and vomiting, so a drug supply system that brings the medication nearer to the mind has benefits.
“We all the time need to have extra choices apart from oral as a result of intranasal formulations keep away from the liver and anybody with liver points can use this drug extra safely in treating migraines,” she mentioned.
Pfizer signed on as a commercialization companion to Biohaven in 2021, paying $500 million up entrance. Biohaven retained U.S. rights whereas Pfizer gained the correct to commercialize Nurtec and Biohaven’s different migraine compounds all over the place else. Practically a 12 months in the past, Nurtec received approvals in Europe for each acute migraine and migraine prevention. Quickly after, Pfizer determined to seize all the advantages of the Biohaven migraine portfolio. Final Could, the pharmaceutical big agreed to pay $11.6 billion to accumulate Biohaven.
In accordance with Royalty Pharma’s 2022 annual report, the corporate is entitled to a 2.1% royalty on the annual mixed world gross sales of Nurtec and Zavzpret as much as $1.5 billion, and a 1.5% royalty on annual mixed world gross sales above $1.5 billion. The deal additionally pays a 3.0% incremental royalty on web worldwide Zavzpret gross sales as much as $1.5 billion and an as much as 2.0% incremental royalty on world gross sales above $1.5 billion. Royalty Pharma estimates its royalties for the migraine medication will finish between 2034 and 2036.
Picture: PixelsEffect, Getty Pictures
